Literature DB >> 33025533

Clinical implications of ANCA positivity in a hospital setting: a tertiary center experience.

Bashar Fteiha1, Alon Bnaya2,3, Marwan Abu Sneineh2, Gideon Nesher2,4,5, Gabriel Simon Breuer2,4,5.   

Abstract

ANCA testing plays an established critical role in the diagnosis of ANCA Associated vasculitis (AAV). The spectrum of diseases associated with positive ANCA has recently broadened, thus calling into question the diagnostic implications of ANCA positivity in a hospital setting. We retrospectively studied all adult patients who had a positive ANCA test (by Indirect Immunofluorescence (IIF), ELISA or both) performed over the span of 19 years. Subjects were then divided into discordant (positive on one assay) and concordant ANCA (positive on both assays) groups based on their ANCA positivity status. The two groups were then compared with regards to their demographic, clinical and laboratory characteristics, the indication for ANCA testing in both groups and their final diagnoses. Of the 9189 ANCA tests ordered during the 19-year span of the study, 389 (4.2%) were positive. Two hundred and forty subjects met the exclusion criteria (patients aged less than 18 years or the lack of clinical and laboratory data in the medical file) thus resulting in a final cohort of 149 subjects. Of them, 122 subjects had discrepant ANCA results and 27 had matching ANCA results. Most cases in the discrepancy group were IIF positive and ELISA negative (86.8%). The diagnosis of AAV was highly unlikely in cases with discrepant IIF and ELISA serologies compared to cases with matching IIF and ELISA serologies (4.1% versus 44.4%, p value < 0.001). The diagnosis of AAV in unlikely in subjects with discrepancies between IIF and ELISA, particularly with only positive IIF.

Entities:  

Keywords:  ANCA; ANCA associated vasculitis; ELISA; Immunofluorescence; Vasculitis

Year:  2020        PMID: 33025533     DOI: 10.1007/s11739-020-02518-6

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  19 in total

1.  Anti-cathepsin G antibodies in the sera of patients with ulcerative colitis.

Authors:  T Kuwana; Y Sato; M Saka; Y Kondo; M Miyata; K Obara; T Nishimaki; R Kasukawa
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

2.  Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.

Authors:  D F Arnold; A Timms; R Luqmani; S A Misbah
Journal:  J Clin Pathol       Date:  2010-08       Impact factor: 3.411

Review 3.  Antineutrophil cytoplasmic antibodies (ANCA).

Authors:  A Radice; R A Sinico
Journal:  Autoimmunity       Date:  2005-02       Impact factor: 2.815

4.  Classification of vasculitis: EMA classification using CHCC 2012 definitions.

Authors:  Rita Abdulkader; Suzanne E Lane; David G I Scott; Richard A Watts
Journal:  Ann Rheum Dis       Date:  2013-06-01       Impact factor: 19.103

Review 5.  Antineutrophil cytoplasmic antibodies.

Authors:  G S Hoffman; U Specks
Journal:  Arthritis Rheum       Date:  1998-09

Review 6.  ANCA in diseases other than systemic vasculitis.

Authors:  H H Peter; D Metzger; A Rump; E Röther
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

Review 7.  International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)

Authors:  J Savige; D Gillis; E Benson; D Davies; V Esnault; R J Falk; E C Hagen; D Jayne; J C Jennette; B Paspaliaris; W Pollock; C Pusey; C O Savage; R Silvestrini; F van der Woude; J Wieslander; A Wiik
Journal:  Am J Clin Pathol       Date:  1999-04       Impact factor: 2.493

Review 8.  Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.

Authors:  Xavier Bossuyt; Jan-Willem Cohen Tervaert; Yoshihiro Arimura; Daniel Blockmans; Luis Felipe Flores-Suárez; Loïc Guillevin; Bernhard Hellmich; David Jayne; J Charles Jennette; Cees G M Kallenberg; Sergey Moiseev; Pavel Novikov; Antonella Radice; Judith Anne Savige; Renato Alberto Sinico; Ulrich Specks; Pieter van Paassen; Ming-Hui Zhao; Niels Rasmussen; Jan Damoiseaux; Elena Csernok
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

9.  Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy?

Authors:  Lisa A Mandl; Daniel H Solomon; Ellison L Smith; Robert A Lew; Jeffrey N Katz; Robert H Shmerling
Journal:  Arch Intern Med       Date:  2002-07-08

10.  Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA).

Authors:  M V Talor; J H Stone; J Stebbing; J Barin; N R Rose; C L Burek
Journal:  Clin Exp Immunol       Date:  2007-07-05       Impact factor: 4.330

View more
  1 in total

1.  ANCA testing: where are we now?

Authors:  Milena Bond; Filippo Fagni; Augusto Vaglio
Journal:  Intern Emerg Med       Date:  2021-01-01       Impact factor: 3.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.